Gut-immune axis and cardiovascular risk in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Microbiology

Background:

• Patients with chronic kidney disease (CKD) experience significant cardiovascular morbidity and mortality.
• Inflammation is increasingly recognized as a key factor driving cardiovascular disease (CVD) progression in CKD.
• The gut microbiome's role in regulating immunity and inflammation is crucial, with growing importance in CKD.

Purpose of the Study:

• To summarize current knowledge on the interplay between gut microbiome dysbiosis, inflammation, and cardiovascular disease (CVD) in CKD.
• To elucidate how changes in bacterial and host metabolism due to CKD-related microbiome alterations contribute to CVD.
• To identify potential therapeutic strategies targeting the gut-immune-cardiovascular axis for managing CVD in CKD.

Main Methods:

• Literature review and synthesis of recent research findings.
• Analysis of studies investigating microbiome composition in CKD patients.
• Examination of research on immune responses and metabolic changes linked to CKD and gut dysbiosis.

Main Results:

• CKD is associated with significant gut microbiome dysbiosis.
• Dysbiosis leads to altered bacterial and host metabolism, promoting systemic inflammation.
• This inflammation is a significant driver of cardiovascular disease (CVD) development and progression in CKD.

Conclusions:

• The gut microbiome plays a critical role in the pathogenesis of CVD in CKD through immune and metabolic dysregulation.
• Targeting the gut-immune-cardiovascular axis presents a promising therapeutic avenue.
• Interventions aimed at modulating the gut microbiome could reduce cardiovascular risk and mortality in CKD patients.